With a view to attain self-reliance and reduce import dependence in critical APIs, a scheme called “Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) In India” was approved by the Government. The total outlay of the scheme is Rs.6,940 crore and financial incentive under the scheme is provided to the selected participants on incremental sales of 41 identified products in four different Target Segments for a period of six years.
Another Scheme called “Production Linked Incentive Scheme for Pharmaceuticals” was approved by the Government of India in March 2021 to enhance India’s manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The total outlay of the scheme is Rs. 15,000 crore and financial incentives are provided to the selected participants on incremental sales for a period of six years.
Under the PLI Scheme for Bulk Drugs, 50 applicants have been approved. Whereas under the PLI Scheme for Pharmaceuticals, 55 applicants have been approved. The details of approved applicants under both the Schemes are available at the website of the Department, viz., pharmaceuticals.gov.in.
The information was given by the Union Minister of Chemicals and Fertilizers, Dr Mansukh Mandaviya in a written reply in the Rajya Sabha today.
Disclaimer : This is an official press release by PIB.